- Article
A Systemic Immune Inflammation Index and PD-L1 (SP142) Expression as a Potential Combined Biomarker of the Clinical Benefit of Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer
- Jong-Min Baek,
- Hyungkeun Cha,
- Yeonsook Moon,
- Lucia Kim,
- Seung Min Kwak,
- Eun Sun Park and
- Hae-Seong Nam
Background: No studies have identified combined biomarkers that may be more reasonable for the assessment of current chemo-immunotherapy in patients with extensive stage small-cell lung cancer (ES-SCLC). Methods: This study was conducted to investiga...

